Alliqua BioMedical Investor Presentation August 2017 NASDAQ: ALQA
|
|
- Victoria Parker
- 6 years ago
- Views:
Transcription
1 Alliqua BioMedical Investor Presentation August 2017 NASDAQ: ALQA
2 Forward Looking Statements Safe Harbor Statement This presentation contains forward-looking statements. Forward-looking statements are generally identifiable by the use of words like "may," "will," "should," "could," "expect," "anticipate," "estimate," "believe," "intend," or "project" or the negative of these words or other variations on these words or comparable terminology. Such statements are based on management's good faith expectations and are subject to numerous factors, risks and uncertainties that may cause actual results, the outcome of events, timing and performance to differ materially from those expressed or implied by such statements. These factors, risks and uncertainties include, but are not limited to, the adequacy of the Company s liquidity to pursue its complete business objectives; inadequate capital; the Company s ability to obtain and retain sufficient reimbursement from third party payers for its products; loss orsafe retirement Harbor of key Statement executives; adverse economic conditions or intense competition; loss of a key customer or supplier; entry of new competitors and products; adverse federal, state and local government regulation; technological obsolescence of the Company s products; technical problems with the Company s research and products; the Company s ability to expand its business through strategic acquisitions; the Company s ability to integrate acquisitions and related businesses; price increases for supplies and components; and the inability to carry out research, development and commercialization plans. In addition, other factors that could cause actual results to differ materially are discussed in our filings with the SEC, including our Annual Report on Form 10-K and our Quarterly Reports on Form 10-Q. Investors and security holders are urged to read these documents free of charge on the SEC's web site at We undertake no obligation to publicly update or revise our forward-looking statements as a result of new information, future events or otherwise.
3 Investment Highlights Regenerative Technology Company that commercializes differentiated products which assist the body in the repair of human tissue. YTD Product Growth (H1/17-H1/16) is 31%. Biologics growth YTD 6/30/17 141% Enjoys a favorable reimbursement position with 97% of Medicare covered lives reimbursed. A strong and growing portfolio of efficacious clinical data. Strong Product Gross Margin 75%. Delivering P&L leverage in 2017 and beyond. Launched one new product (Interfyl) in late Q3/16 with better than expected performance. 2
4 Company Highlights Two core technology platforms focusing on two key verticals. Celgene Corporation is the largest shareholder and holds one board seat. MIST Therapy is well positioned to change the Standard of Care in the protocol of venous leg ulcers. Celularity, Alliqua s development partner, enjoys an exciting pipeline of new technologies; truly Transforming Life, which create further product opportunities for Alliqua. 3
5 Alliqua BioMedical The Vision RESTORING TISSUE. REBUILDING LIVES. To build a leading regenerative technology company that commercializes differentiated regenerative medical products which assist the body in the repair of human tissue. Due to their clinical efficaciousness and cost effectiveness, we believe these products will enhance the quality of life to patients and build shareholder value. 4
6 Experienced & Committed Management Team and Board Management Name Title Previous Employers David Johnson Chief Executive Officer, Director Chief Executive Officer Division President Brian Posner Chief Financial Officer Chief Financial Officer Brad Barton Chief Operating Officer President of ConvaTec Americas Nino Pionati Chief Strategy and Marketing Officer VP of Marketing President of Global Marketing & B.D. VP of Marketing Gregory Robb VP of Operations VP of Operations Board of Directors Name Experience Name Experience Dr. Jerome Zeldis (Chairman) Winston Kung* Jeffrey Sklar Chief Medical Officer Chief Medical Officer VP - Business Development CBO - Celgene Cellular Therapeutics Dir. - Healthcare Investment Banking VP - Global M&A Managing Partner Joseph Leone Gary Restani Mark Wagner * Celgene Corporation is Alliqua BioMedical s largest shareholder, and enjoys one designated board seat. Chief Financial Officer President & CEO President Division President Division President President & CEO President & CEO Product Manager
7 Alliqua BioMedical Delivering Sustainable Growth with Attractive Gross Margins ANNUAL TOTAL GAAP REVENUE ($M) $25 $20 1H 16 VS 1H 17 PRODUCT REVENUE ($M) $15 $10 $10 $5 $8 $ Guidance Alliqua Products Contract Manufacturing $6 $4 Product Growth 31% H1/17 vs H1/16 Attractive Product Gross Margins 75% Biologics Growth YTD 141% $2 $0 1 H'16 1 H'17 6
8 2017 Growth Drivers Drive newly launched Interfyl (late Q3/16 Launch) into the surgical market. Expand the hybrid selling model approximately 30 Independents Accelerate the Peer to Peer engagement initiatives through: Executing on the Biologics Skill Labs Introducing UltraMIST Physician Summits Expanding local and regional education forums Leveraging a compelling Economic Value Proposition Expanding on our sound Clinical Evidence Focus resources on Where Alliqua Can Win 7
9 Alliqua Focuses on the Advanced Wound and Tissue Repair Market - Compelling Market Size $8 Billion Global advanced wound care market estimated at $8+ Billion (1) The U.S. represents more than 1/3 rd of the global market The U.S. market is highly fragmented among private and micro-cap companies as well as large diversified companies Large and growing patient population Growth in wound incidence expected due to demographic trends in obesity ACUTE WOUNDS CHRONIC WOUNDS Wound Type Burn Wounds Trauma Wounds Surgical Wounds Diabetic Foot Ulcers Pressure Ulcers Venous Leg Ulcers Arterial Ulcers Incidence (2) ~460,000 per year ~430,000 per year ~4.7 million per year ~1.5 million per year ~4.6 million per year ~1.0 million per year ~250,000 per year $8+ Billion Total Addressable Market (1) Areas of Focus 8 (1) Source: 2012 Kalorama Information Wound Care Markets 2012 and Alliqua BioMedical management estimates (2) Smart Trak
10 Biologics A Fast, Growing & Sustainable Market Fastest growing sector today and tomorrow Diabetes, obesity & the aging population will continue to drive demand Technological advancements will sustain growth In 2016, Alliqua grew sales of its biologic products in excess of 115% 9
11 Building the Regenerative Technology Portfolio The Criteria Unique differentiated Risk Adjusted regulatory & reimbursement Clinically efficacious Economic value proposition Strong margin profile Targeting Regenerative medicine products for Advanced Wounds and Tissue Repair
12 Strong Existing Product Portfolio Focused on driving growth of our high-value regenerative technologies Regenerative Technologies Human Placental Tissue Based Treatments Cell Stimulation Antimicrobial Protection 11
13 BIOVANCE: Acellular Amniotic Membrane Allograft Capturing share in a rapidly expanding biologics market PRODUCT OVERVIEW & FEATURES BIOVANCE is an amniotic membrane allograft derived from placental tissue BIOVANCE acts as a barrier membrane and is intended to protect underlying tissue and preserve tissue plane boundaries with minimized adhesion and scar formation The natural function of the amniotic brings protection and support to the wound it covers Acellular composition reduces inflammation Supports tissue growth Provides a biological barrier to infection Minimizes pain upon application Maintains a moist wound environment REIMBURSEMENT COVERAGE PRODUCT SALES TRAJECTORY Biovance Q Q Q Q Q Q Q Q Q Q CLINICAL SUPPORT Attractive Reimbursement Coverage Hospital Outpatient Department 93% Medicare Covered Lives Expanding Commercial Coverage Surgery - DRG 12 *Source: SmartTRAK data
14 Interfyl Alliqua s Second Entry Into the Biologics Market Strong commercial traction since launch in September 2016 PRODUCT OVERVIEW & FEATURES FDA Cleared, 361 Product Extracellular connective tissue matrix Replaces damaged integumental soft tissue Provides mechanical and structural support to facilitate the tissue repair process Offered in both particulate and flowable forms Can be used to fill voids and correct defects in soft tissue Broad range of surgical indications, including lower extremity applications METHOD OF ACTION Interfyl provides a scaffold for fibroblasts & keratinocytes to attach to & proliferate Total Sales - Interfyl $400,000 $300,000 $200,000 $100,000 $2016 Q Q Q Q Q2 13
15 World Class Development Partner.. Harnessing the power of placenta-derived cells to amplify the body s ability to fight disease, heal and regenerate itself 14
16 UltraMIST Therapy Ultrasound Healing Therapy - Changing Standard of Care TREATMENT OVERVIEW & FEATURES UltraMIST Therapy is a painless, noncontact, low frequency ultrasound delivered through a saline mist to the wound bed The only known noncontact, low-frequency, ultrasound device cleared by the FDA One of only two medical devices with an indication to promote wound healing UltraMIST uses the ultrasound waves to stimulate the cells below the wound bed surface, a region that was previously inaccessible to wound care practitioners Accelerates healing and wound closure Reduces wound inflammation and bacteria/bioburden Increases blood flow to the afflicted area KEY HIGHLIGHTS Favorable Reimbursement 100% Medicare Coverage Potential Standard of Care Game Changer High margin profile CE Mark CLINICAL DATA Large and Compelling Portfolio of Clinical Support PATENT POSITION 17 U.S. Patents 17 O.U.S. Patents 1 New Patent Pending on UltraMIST as a Delivery System for Biologics 15
17 Alliqua Markets their product through a Hybrid Sales & Distribution Infrastructure Continuing to enhance our distribution capabilities Hybrid Sales Organization: ~ 35 Direct selling resources + ~ agent principals Product Supply Group Purchasing Agreements (GPO Contracts) 16
18 Sustainable Alliqua Product Growth Expecting Strong Double Digit Products Growth in Products growth to be fueled by regenerative therapies: Expecting continued strong sales growth in biologics portfolio with contributions from UltraMIST $20 $15 Revenue ($M) $10 $5 $ Guidance ALQA Products 17
19 Financial Highlights ($, 000s) Q Q % Change Products Revenue $4,917 $3,658 34% Total Revenue: $5,522 $4,467 24% Gross Margin: 66% 64% 3% SGA, less stock-based compensation, depreciation and amortization expenses Adjusted EBITDA loss from continued operations* $5,696 $7,017 <19%> ($2,018) ($4,485) <55%> Headcount <21%> *Non-GAAP Measurement, See table in August 10, 2017 press release for reconciliation to GAAP results 18
20 Alliqua BioMedical Strategic Direction Products / Technology BIOVANCE Interfyl UltraMIST Expand through: Development; Distribution and Licensing Vertical Indications Expand through Orthopedics and Chronic Wounds Sales Force Expansion Positioning for a Long Term Shareholder Value Outcomes Sustainable, Market Leading Growth Scaled for Strong Profitability Complete Portfolio Positioning for Global Health Technological Advancement through combination therapies Productive, Geographically Diverse Sales Organization Expand geographically with Direct Representation and Market Leading Agents 19
21 Nasdaq: ALQA Alliqua BioMedical, Inc Stony Hill Road, Suite 200 Yardley, PA (215)
Anika Therapeutics, Inc.
Anika Therapeutics, Inc. Jefferies Global Healthcare Conference June 4, 2015 Safe Harbor Statement The statements made in this presentation that are not statements of historical fact are forward looking
More informationAnika Therapeutics, Inc.
Anika Therapeutics, Inc. Canaccord Genuity 34th Annual Growth Conference August 14 th, 2014 Safe Harbor Statement The statements made in this presentation, which are not statements of historical fact,
More informationDeutsche Bank Health Care Conference
Deutsche Bank Health Care Conference May 8, 2018 NASDAQ: ANIK0 Safe Harbor Statement The statements made in, and during the course of, this presentation that are not statements of historical fact, including
More informationJefferies TMT Conference
Jefferies TMT Conference Tarek Sherif, Chairman and CEO Cory Douglas, CFO May 9, 2013 2013 Medidata Solutions, Inc. 1 Safe Harbor Statement This presentation contains forward-looking statements within
More informationInvestor Presentation May 2018
Investor Presentation May 2018 FORWARD-LOOKING STATEMENTS Forward-Looking Statements Certain statements and information in this communication may be deemed to be forward-looking statements within the meaning
More informationNASDAQ: EYES. Investor Presentation
Investor Presentation 2016 Forward Looking Statements This presentation contains certain forward looking information about Second Sight that is intended to be covered by the safe harbor for "forward looking
More informationTeva Pharmaceutical Industries Ltd. J.P. Morgan Healthcare Conference. Kåre Schultz President and CEO January 7, 2019
Teva Pharmaceutical Industries Ltd. J.P. Morgan Healthcare Conference Kåre Schultz President and CEO January 7, 2019 Cautionary Note Regarding Forward-Looking Statements 2 This presentation contains forward-looking
More informationINVESTOR PRESENTATION THIRD QUARTER 2016 SAJAN.COM PUBLIC DOCUMENT SAJAN, INC NASDAQ: SAJA
INVESTOR PRESENTATION THIRD QUARTER 2016 SAFE HARBOR The Private Securities Litigation Reform Act of 1995 provides a safe harbor from liability for certain forward-looking statements. This presentation
More informationA Leading Global Health Care Group
A Leading Global Health Care Group Frankfurt stock exchange: FRE US ADR program: FSNUY www.fresenius.com/investors General Presentation, Fresenius SE & Co. KGaA, Investor Relations Copyright, August 2016
More informationCEO s Round Table June
CEO s Round Table June 2009 0 Forward looking statements This presentation contains certain "forward-looking statements" within the meaning of the US Private Securities Litigation Reform Act of 1995. In
More information20 years. Healed! What did he say? Just got home from the doctor. How s Dad?
2 0 1 2 A N N U A L R E P O R T How s Dad? Just got home from the doctor. What did he say? Healed! 20 years of stem cell research, development, and global leadership distilled into the only word that matters
More informationCautions Concerning Forward-looking Statements
1 Cautions Concerning Forward-looking Statements These presentations contain forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995 regarding, among other things,
More informationJ.P. Morgan Healthcare Conference January 10, 2018
J.P. Morgan Healthcare Conference January 10, 2018 Safe Harbor This presentation is intended to be disclosure through methods reasonably designed to provide broad, non-exclusionary distribution to the
More informationSupplemental Financial Schedules May 19, 2015
Supplemental Financial Schedules May 19, 2015 The presentations and related schedules contain financial measures that are not calculated in accordance with generally accepted accounting principles (GAAP).
More informationA LEADING GLOBAL HEALTH CARE GROUP. Frankfurt stock exchange (DAX30): FRE US ADR program (OTC): FSNUY
A LEADING GLOBAL HEALTH CARE GROUP Frankfurt stock exchange (DAX30): FRE US ADR program (OTC): FSNUY www.fresenius.com/investors SAFE HARBOR STATEMENT This presentation contains forward-looking statements
More informationNuVasive, Inc. Acquisition of Ellipse Technologies, Inc. January 5, 2016
NuVasive, Inc. Acquisition of Ellipse Technologies, Inc. January 5, 2016 Safe Harbor Statements Forward-looking information and non-gaap measures NuVasive, Inc. ( NuVasive, NUVA or the Company ) cautions
More informationJefferies 2014 Global Healthcare Conference June 3, 2014 NYSE: Q
Jefferies 2014 Global Healthcare Conference June 3, 2014 NYSE: Q Copyright 2013 Quintiles Forward Looking Statements and Use of Non-GAAP Financial Measures This presentation contains forward-looking statements
More informationFORWARD LOOKING STATEMENTS
Jefferies 2014 Healthcare Conference November 19, 2014 FORWARD LOOKING STATEMENTS This presentation contains forward looking statements. Any statements contained herein which do not describe historical
More information35th Annual J.P. Morgan Healthcare Conference
35th Annual J.P. Morgan Healthcare Conference Investor Presentation Nachum Homi Shamir President and Chief Executive Officer January, 2017 Safe Harbor Statement Certain statements made during the course
More informationTodd M. Pope President & CEO. Stifel 2017 Healthcare Conference November 14, 2017
Todd M. Pope President & CEO Stifel 2017 Healthcare Conference November 14, 2017 3 Forward Looking Statements This presentation includes statements relating to TransEnterix s current regulatory and commercialization
More informationHealth Care Business Group
Health Care Business Group Joaquin Delgado, Executive Vice President December 17, 2013 2013 3M. All Rights Reserved. 2 3M CONFIDENTIAL 2013 3M. All Rights Reserved. Saving and improving lives around the
More informationGeneral Employment Announces Results for Fiscal 2015 Fourth Quarter and Year End
December 30, 2015 General Employment Announces Results for Fiscal 2015 Fourth Quarter and Year End Company Provides Combined Select Pro Forma Financial Information NAPERVILLE, IL -- (Marketwired) -- 12/30/15
More information2018 Q1 Investor Relations Presentation
2018 Q1 Investor Relations Presentation Forward Looking Statements This presentation contains forward-looking statements. Statements that are predictive in nature, that depend upon or refer to future events
More informationA Leading Provider of Marketing Automation Solutions
A Leading Provider of Marketing Automation Solutions Investor Presentation December 2017 SharpSpring, Inc. investors.sharpspring.com NASDAQ: SHSP Safe Harbor Statement The information provided in this
More informationOverview and Progress Update: Medicare Performance Initiative (MPI)
Overview and Progress Update: Medicare Performance Initiative (MPI) Britt Reynolds, President Hospital Operations Scott Richardson, Senior Vice President Operations Finance and Performance Management &
More informationMDGS.TASE MDGS.Nasdaq March 2017
Issuer Free Writing Prospectus dated March 21, 2017 Filed Pursuant to Rule 433 Registration Statement No. 333-216155 MDGS.TASE MDGS.Nasdaq March 2017 Forward looking statements This presentation may contain
More informationNew Cardinal Health (Post-Spin)
New Cardinal Health (Post-Spin) George Barrett Vice Chairman and Chief Executive Officer Healthcare Supply Chain Services and Chief Executive Officer Cardinal Health, Inc. (post-spin) January 14, 2009
More informationSpray-on stem cells for rapid healing.
Spray-on stem cells for rapid healing. Grafting is Painful, Expensive and Leaves Scarring Inadequate Options for Burn Patients Skin Grafting is Current Standard-of-Care Sheets of meshed skin for surgical
More informationInvestor Presentation. November 2016
Investor Presentation November 2016 Safe Harbor Statement The statements in this presentation that relate to guidance, pro forma presentations, future plans, goals, business opportunities, events or performance
More informationCambrex Cell Therapy. Buckingham Research Conference Call
Cambrex Cell Therapy Buckingham Research Conference Call April 14, 2005 Safe Harbor Statement Today s presentation and discussion will contain forward-looking statements including statements regarding
More informationInvestor Presentation. November 26, 2013
Investor Presentation November 26, 2013 Forward-Looking Statements This presentation may contain forward-looking statements as defined under U.S. federal securities laws. These statements reflect management's
More informationGOLDMAN SACHS GLOBAL HEALTHCARE CONFERENCE June 14, 2017
GOLDMAN SACHS GLOBAL HEALTHCARE CONFERENCE June 14, 2017 Forward Looking Statements Statements in this presentation that are not strictly historical, including any statements regarding events or developments
More informationINVESTOR PRESENTATION. Merge Healthcare January 2012
INVESTOR PRESENTATION Merge Healthcare January 2012 forward looking statement 2 The matters discussed in this presentation may include forward-looking statements, which could involve a number of risks
More informationMylan. Raymond James 40 th Annual Institutional Investors Conference March 05, 2019
Mylan Raymond James 40 th Annual Institutional Investors Conference March 05, 2019 Forward-Looking Statements This presentation contains forward-looking statements. These statements are made pursuant to
More informationJP Morgan Healthcare Conference. 11 January 2010
JP Morgan Healthcare Conference 11 January 2010 Forward looking statements This presentation contains certain "forward-looking statements" within the meaning of the US Private Securities Litigation Reform
More informationJefferies 2016 Healthcare Conference. June 7, 2016
Jefferies 2016 Healthcare Conference June 7, 2016 Forward Looking Statements This presentation and the accompanying oral presentation contain forward-looking statements that are based on our management
More informationThird Quarter 2014 Earnings Conference Call Prepared Remarks November 5, 2014
Third Quarter 2014 Earnings Conference Call Prepared Remarks November 5, 2014 Bonnie Hyun: Thank you. Welcome to our third quarter 2014 earnings call. With me on the call today are Scott Lang, our Chief
More informationPluristem Issues Letter to Shareholders
Pluristem Issues Letter to Shareholders HAIFA, Israel, January 30, 2014 -- Pluristem Therapeutics Inc. (NASDAQCM: PSTI) (TASE:PLTR), a leading developer of placenta-based cell therapies, today issued a
More informationJefferies 2015 Global Healthcare Conference June 3, 2015
Jefferies 2015 Global Healthcare Conference June 3, 2015 Forward-Looking Statements This document may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act
More informationThe Innovator in Healthcare Workforce Solutions & Staffing Services. Investor Presentation Q1 2014
The Innovator in Healthcare Workforce Solutions & Staffing Services Investor Presentation Q1 2014 Forward-Looking Statements This investor presentation contains "forward-looking statements" within the
More information34 th Annual J.P. Morgan Healthcare Conference
34 th Annual J.P. Morgan Healthcare Conference Vincent A. Forlenza Chairman, Chief Executive Officer and President January 13, 2016 Forward-Looking Statements These materials include forward-looking statements
More informationInvestor Presentation. November, 2015
Investor Presentation November, 2015 1 Disclaimer These slides contain (and the accompanying oral discussion will contain) forward looking statements. All statements other than statements of historical
More informationJEFFERIES 2015 GLOBAL HEALTHCARE CONFERENCE JUNE 3, 2015 NACHUM HOMI SHAMIR PRESIDENT AND CHIEF EXECUTIVE OFFICER
JEFFERIES 2015 GLOBAL HEALTHCARE CONFERENCE JUNE 3, 2015 NACHUM HOMI SHAMIR PRESIDENT AND CHIEF EXECUTIVE OFFICER SAFE HARBOR STATEMENT Certain statements made during the course of this presentation may
More informationRTIX Investor Presentation
RTIX Investor Presentation Camille Farhat President and CEO Jonathon Singer CF&AO September 2018 Forward Looking Statements This communication contains forward-looking statements within the meaning of
More informationAVITA Medical RECELL System Health Economic Data Projects USD $28 Million in Annual Savings at a Single Major Burn Center Versus Standard of Care
ASX/News Release AVITA Medical RECELL System Health Economic Data Projects USD $28 Million in Annual Savings at a Single Major Burn Center Versus Standard of Care Additional data presented at ABA Annual
More information37 th Annual J.P. Morgan Healthcare Conference
37 th Annual J.P. Morgan Healthcare Conference Ronald Rittenmeyer, Executive Chairman and CEO January 8, 2019 1 FORWARD-LOOKING STATEMENTS This presentation includes forward-looking statements. These statements
More informationNEXT GENERATION ECM-BASED ALLOGRAFT TECHNOLOGY:
NEXT GENERATION ECM-BASED ALLOGRAFT TECHNOLOGY: Potent biological scaffolds strategically control stem cell fate and function, allowing our allografts to harness the regenerative potential of patient s
More informationCollagen Solutions Plc
Collagen Solutions Plc Jamal Rushdy, CEO Growth & Innovation Forum 2017 January 2017 Disclaimer This presentation is incomplete without reference to, and should be viewed solely in conjunction with the
More informationINVESTOR PRESENTATION. February 2012
INVESTOR PRESENTATION February 2012 1 FORWARD-LOOKING STATEMENTS We will be making forward-looking statements during today s presentation. Please refer to the appendix of this presentation and our most
More informationA review of Dr. Dinakar Golla s clinical research with AdMatrix surgical grafts for soft tissue repair
TEAMeffort: Using aggressive surgical techniques in combination with AdMatrix (Lattice Biologics acellular dermal scaffold product) to heal difficult and persistent wounds A review of Dr. Dinakar Golla
More informationSecond Quarter 2017 Earnings Teleconference. August 1, 2017
Second Quarter 2017 Earnings Teleconference August 1, 2017 Introduction Chuck Triano Senior Vice President, Investor Relations Forward-Looking Statements and Non-GAAP Financial Information 3 Our discussions
More informationFORWARD LOOKING STATEMENT
FORWARD LOOKING STATEMENT Statements made in this presentation that look forward in time or that express management's beliefs, expectations, hopes or predictions of the future are forward-looking statements
More informationJefferies 2018 Global Healthcare Conference. June 7, 2018
Jefferies 2018 Global Healthcare Conference June 7, 2018 Forward-Looking Statements Statements in this presentation regarding the future financial and operating results, outlook, growth, prospects, business
More informationInvestor Slides. Needham 20 th Annual Growth Conference January 17, 2018 NASDAQ GS: UEIC
Investor Slides Needham 20 th Annual Growth Conference January 17, 2018 NASDAQ GS: UEIC Safe Harbor Statement During this presentation, Management will reference Adjusted Non-GAAP information, including
More informationThird Quarter 2009 Results. Analysts and Media Conference November 5, 2009 Zurich
Third Quarter 2009 Results Analysts and Media Conference November 5, 2009 Zurich This presentation contains forward looking statements which involve risks and uncertainties. The actual performance, results
More informationINVESTOR PRESENTATION. Merge Healthcare February / March 2012
INVESTOR PRESENTATION Merge Healthcare February / March 2012 forward looking statement 2 The matters discussed in this presentation may include forward-looking statements, which could involve a number
More information2017 Glaukos Corporation. August 2017
August 2017 DISCLAIMER All statements other than statements of historical facts included in this presentation that address activities, events or developments that we expect, believe or anticipate will
More informationSTRATASYS Q May 9 th, 2016 FINANCIAL RESULTS CONFERENCE CALL 1 STRATASYS / THE 3D PRINTING SOLUTIONS COMPANY
STRATASYS Q1 2016 FINANCIAL RESULTS CONFERENCE CALL May 9 th, 2016 1 STRATASYS / THE 3D PRINTING SOLUTIONS COMPANY Q1 2016 Conference and webcast details Speakers David Reis CEO Erez Simha COO & CFO Shane
More informationInvestor Presentation Q1 2019
Investor Presentation Q1 2019 Looking Forward Statements The statements in this presentation relating to matters that are not historical fact are forward looking statements that are based on management's
More informationMarshall & Ilsley Corporation Investor Conference Call
Investor Conference Call statements Forward-Looking Statements This presentation contains certain forward-looking statements based on current management expectations. Those forwardlooking statements include
More informationCORPORATE OVERIVEW MARCH 2019
A Niche Market Growth Company in the U. S. Cannabis Industry CSE: VCAN CORPORATE OVERIVEW MARCH 2019 www.venturacanna.com Disclaimer STIKEMAN Certain statements contained in this presentation constitute
More informationMEDICATION DELIVERY. David Ferguson GM, Medication Delivery. May 21, 2018
MEDICATION DELIVERY David Ferguson GM, Medication Delivery May 21, 2018 Safe Harbor Statement This presentation includes forward-looking statements concerning Baxter s financial results, R&D pipeline,
More informationGE Healthcare healthymagination Investor Update
GE Healthcare healthymagination Investor Update UBS John Dineen President & CEO, GE Healthcare May 6, 2011 "Results are preliminary and unaudited. This document contains forward-looking statements - that
More informationEXANE Conference. Jérôme Contamine, Executive Vice President, Chief Financial Officer. Paris June 13, 2017
EXANE Conference Jérôme Contamine, Executive Vice President, Chief Financial Officer Paris June 13, 2017 Forward Looking Statements This presentation contains forward-looking statements as defined in the
More informationSafe Harbor Statement
May 2004 A leader in the research, manufacturing and marketing of medical devices used in neuro-trauma and neurosurgery, plastic and reconstructive surgery and general surgery Safe Harbor Statement Certain
More information2017 EARNINGS PRESENTATION PeerStream, Inc. Ticker: PEER
2017 EARNINGS PRESENTATION PeerStream, Inc. Ticker: PEER safe harbor This presentation is for discussion purposes only. Certain material is based upon third party information that we consider reliable,
More informationHelping people share life s joy.
2016 Helping people share life s joy. 1 Safe Harbor Disclaimer This presentation contains "forward-looking" statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section
More informationQ Results & Acquisition of Tea Leaves Health
Q2 2015 Results & Acquisition of Tea Leaves Health Safe Harbor During the course of this presentation, we may make forward-looking statements, including statements regarding the company's future financial
More informationTISSUE ENGINEERING AND REGENERATION: TECHNOLOGIES AND GLOBAL MARKETS
TISSUE ENGINEERING AND REGENERATION: TECHNOLOGIES AND GLOBAL MARKETS HLC101B August 2014 Yojana Jeevane Project Analyst ISBN: 1-56965-894-3 BCC Research 49 Walnut Park, Building 2 Wellesley, MA 02481 USA
More informationStephens Fall Investment Conference
Stephens Fall Investment Conference November 8, 2017 Steven M. Klosk President & CEO Forward-Looking Statements This document may contain forward-looking statements within the meaning of the Private Securities
More informationInvestor Presentation RBC Capital Markets Global Healthcare Conference February 22, 2017
Investor Presentation 2017 RBC Capital Markets Global Healthcare Conference February 22, 2017 Forward-Looking Statements This document may contain forward-looking statements within the meaning of the Private
More informationBiopreservation Tools for Cells, Tissues and Organs
Biopreservation Tools for Cells, Tissues and Organs NASDAQ: BLFS Investor Presentation May 2018 Safe Harbor Statement Except for historical information contained herein, this press release contains forward-looking
More informationEsterline Explained. February, This presentation contains no controlled technical data or technology.
February, 2018 This presentation contains no controlled technical data or technology. This presentation may contain "forward-looking statements" within the meaning of the Private Securities Litigation
More informationUnited Kingdom Tissue Engineered - Skin Substitutes Market Outlook to 2020
United Kingdom Tissue Engineered - Skin Substitutes Market Outlook to Reference Code: GDMECC0860DB Publication Date: October 2014 Page 1 1 Table of Contents 1 Table of Contents... 2 1.1 List of Tables...
More informationJefferies Healthcare Conference
Jefferies Healthcare Conference Align Technology, Inc. Shirley Stacy, VP Investor Relations and Corporate Communications June 3, 2014 2014 Align Technology, Inc. All rights reserved. 1 2014 Align Technology,
More informationInvestor Review. May 2017
Investor Review May 2017 Forward-Looking Statements This presentation contains forward-looking statements reflecting our current expectations that involve risks and uncertainties which are subject to safe
More informationIntercytex Group plc
Intercytex Group plc 0 Disclaimer This information contained in this document is being supplied to you solely for your information and may not be copied, reproduced or further distributed to any person
More informationGood day, ladies and gentlemen. Welcome to today s conference call to discuss Stratasys fourth quarter and full year 2016 financial results.
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 SSYS Q4 2016 Earnings Script SLIDE 1 & 2: TITLE SLIDES SPEAKER:
More informationTo our fellow shareholders,
BIOCARDIA, INC. To our fellow shareholders, Another year is completed and I remain optimistic about the strength of our therapeutic programs and the progress we are making. There is intense effort being
More information2008 Citi Investment Research Global Healthcare Conference
2008 Citi Investment Research Global Healthcare Conference Robert J. Colletti Senior Vice President & Chief Financial Officer May 22, 2008 0 Disclosure Statements SAFE HARBOR STATEMENT: FORWARD-LOOKING
More informationFOR IMMEDIATE RELEASE
FOR IMMEDIATE RELEASE Media Contact: Melanie Battista, Public Relations (TSX-V: LBL) (OTCBB: BLVKF) 16701 N 90th Street, Suite#101 Scottsdale, AZ 85260 480-563-0800 Office News@LatticeBiologics.com www.latticebiologics.com
More informationHSCI: the first Russian public biotech company
HSCI: the first Russian public biotech company (expanding into new geographic markets) TEASER for Investor presentation (road-show for sale of 28.6 % of HSCI s increased share capital) June 2014 Disclaimer
More informationExtending our Reach. Investor Presentation, March 1, 2018
Extending our Reach Investor Presentation, March 1, 2018 Looking Forward Statements The statements in this presentation relating to matters that are not historical fact are forward looking statements that
More informationLEVERAGING OUR BIOLOGICS EXPERTISE IN BIOSIMILARS SCOTT FORAKER VICE PRESIDENT AND GENERAL MANAGER, BIOSIMILARS
LEVERAGING OUR BIOLOGICS EXPERTISE IN BIOSIMILARS SCOTT FORAKER VICE PRESIDENT AND GENERAL MANAGER, BIOSIMILARS SAFE HARBOR STATEMENT This presentation contains forward-looking statements that are based
More informationCOUPA: THE CLOUD PLATFORM FOR BUSINESS SPEND MANAGEMENT (BSM) December 4, 2018
COUPA: THE CLOUD PLATFORM FOR BUSINESS SPEND MANAGEMENT (BSM) December 4, 2018 2018 Coupa Software, Inc. All Rights Reserved SAFE HARBOR STATEMENT This presentation and the accompanying oral presentation
More informationpsivida Transforms into Commercial Stage Specialty BioPharmaceutical Company ASCRS April 12, 2018 NASDAQ: EYPT
psivida Transforms into Commercial Stage Specialty BioPharmaceutical Company OIS @ ASCRS April 12, 2018 NASDAQ: EYPT Forward Looking SAFE HARBOR STATEMENTS UNDER THE PRIVATE SECURITIES LITIGATION REFORM
More informationAvnet Presentation Raymond James 38 th Annual Institutional Investors Conference
William Amelio, Chief Executive Officer Vincent Keenan, Senior VP of Investor Relations March 7, 2017 Avnet Presentation Raymond James 38 th Annual Institutional Investors Conference 1 Safe Harbor Statement
More informationWe help build companies of the future
March 2018 Investor Presentation We help build companies of the future By Pat Goepel SAFE HARBOR STATEMENT (Under the Private Securities Litigation Reform Act of 1995) Statements made in this presentation
More informationInvestor Presentation GUY COOK CEO
Investor Presentation GUY COOK CEO FORWARD LOOKING STATEMENTS This presentation contains certain disclosures that may be deemed forward-looking statements within the meaning of the Private Securities Litigation
More informationInvestor Deck. May 2018
Investor Deck May 2018 1 Disclaimer Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements
More informationGermany Tissue Engineered - Skin Substitutes Market Outlook to 2020
Germany Tissue Engineered - Skin Substitutes Market Outlook to 2020 Reference Code: GDMECC0884DB Publication Date: October 2014 Page 1 1 Table of Contents 1 Table of Contents... 2 1.1 List of Tables...
More informationPress Releases Boston Scientific to Acquire Vessix Vascular, Inc.
Press Releases Boston Scientific to Acquire Vessix Vascular, Inc. Company to Strengthen Hypertension Program with Acquisition of Renal Denervation Technology Nov 8, 2012 NATICK, Mass., Nov. 8, 2012 /PRNewswire/
More informationJefferies 2017 Global Healthcare Conference. June 7, 2017
Jefferies 2017 Global Healthcare Conference June 7, 2017 Forward-Looking Statements This document may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act
More informationBiopreservation Tools for Cells, Tissues and Organs
Biopreservation Tools for Cells, Tissues and Organs NASDAQ: BLFS Investor Presentation March 2018 Safe Harbor Statement Except for historical information contained herein, this press release contains forward-looking
More information2018 Investor Presentation
1 1-800-FLOWERS.COM,INC. 2018 Investor Presentation 2 Our Vision Help Our Customers Express, Connect and Celebrate Our Mission Deliver Smiles! 3 FLWS: A Compelling Investment Opportunity Accelerating revenue
More informationForward Looking Statements
Forward Looking Statements All of the information presented that is not historical in nature should be considered to be forward-looking statements that are subject to certain risks, uncertainties or assumptions
More informationSanten Acquisition of InnFocus, Developer of MicroShunt Glaucoma Implant Device
Santen Acquisition of InnFocus, Developer of MicroShunt Glaucoma Implant Device Akira Kurokawa President & CEO August 2, 2016 Copyright 2016 Santen Pharmaceutical Co., Ltd. All rights reserved. 1 External
More informationTodd M. Pope President & CEO. JP Morgan Healthcare Conference January 8, 2018
1 Todd M. Pope President & CEO JP Morgan Healthcare Conference January 8, 2018 3 Forward Looking Statements This presentation includes statements relating to TransEnterix s current regulatory and commercialization
More informationInvestor Relations Presentation
Kinetic Concepts, Inc. Investor Relations Presentation Fourth Quarter 2008 Forward-Looking Statement This presentation contains forward-looking statements including, among other things, management's outlook,
More informationInvestor Presentation
Investor Presentation As of February 5, 2018 Advanced Signal Processing Products Safe Harbor Statement Except for historical information contained herein, the matters set forth in this presentation contain
More information